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Kaposi’s sarcoma-associated herpesvirus (KSHV) replication and transcription activator (RTA) is
well established as a key transcriptional activator that regulates the KSHV life cycle from latency
to lytic replication. It is expressed immediately after infection and activates a number of viral genes
leading to virus replication. The RTA-responsive element (RRE) in the RTA target gene promoters
is critical for RTA to mediate this transactivation. A number of non-conserved RREs have been
identified in various RTA-responsive promoters, and AT-rich sequences have been proposed to
serve as RTA targets, but no consensus RRE sequence has been identified so far. Two non-
conserved RREs (RRE1 and RRE2) containing AT-rich sequences have been identified previously
in the promoter of one of the KSHV lytic genes, ORF57, which can be strongly activated by RTA.
Based on homology with the consensus sequence of the Epstein–Barr virus Rta RRE, this study
identified a third RTA-responsive element (RRE3) in the ORF57 promoter. This RRE comprised a
GC-rich sequence that could bind RTA both in vitro and in vivo, and plays a role in RTA-mediated
transactivation of the ORF57 promoter. The presence of two of the three RREs in close proximity
to each other was required for optimal RTA-mediated transactivation of the ORF57 promoter,
even though the presence of only one RRE is needed for RTA binding. These results suggest that
the ability of RTA to mediate transcriptional activation is distinct from its ability to bind to its target
elements.
INTRODUCTION
Kaposi’s sarcoma-associated herpesvirus (KSHV; human
herpesvirus 8) was first identified from Kaposi’s sarcoma
tissue of an AIDS patient in 1994 and subsequently shown
to be associated with Kaposi’s sarcoma and other
malignancies, including primary effusion lymphoma and
multicentric Castleman’s disease (Cesarman et al., 1995a, b;
Chang et al., 1994). According to nucleotide sequence
analysis, KSHV belongs to the genus Rhadinovirus in the
subfamily Gammaherpesvirinae, with family members that
include Epstein–Barr virus (EBV) and herpesvirus saimiri
(Russo et al., 1996). As in all herpesviruses, KSHV goes
through latent and lytic phases of infection, with latency
predominantly found in infected B cells (Staskus et al.,
1997). During latency, a small subset of viral genes is
expressed in order to evade the immune response and
maintain the viral genome in the host cells. These latent
proteins have also been found to affect the survival and
proliferation of infected cells in vitro (Friborg et al., 1999;
Radkov et al., 2000; Rivas et al., 2001; Sharp et al., 2002;
Sturzl et al., 1999). Virus lytic replication can be reactivated
in vitro by treatment with chemical agents such as sodium
butyrate or tetradecanoylphorbol acetate (Miller et al.,
1997) and in vivo by the KSHV-encoded transcription
factor RTA (replication and transcription activator) (Lukac
et al., 1998). Upon reactivation from latency, lytic viral
proteins are induced and expressed. These proteins are
encoded by differentially expressed genes; the immediate-
early genes are transcribed first, followed by expression of
early genes, and the late genes are expressed after viral DNA
replication (Sun et al., 1999).
RTA is an important viral regulatory protein encoded by
the immediate-early gene ORF50. A striking feature of RTA
is its ability to trigger KSHV lytic reactivation by itself in
latently infected cells (Gradoville et al., 2000; Lukac et al.,
1998, 1999; Staskus et al., 1997; Sun et al., 1998), and
KSHV with an RTA gene deletion is incapable of lytic
reactivation (Xu et al., 2005). Therefore, RTA has been
implicated as an important switch to control the transition
from KSHV latency to lytic replication. The RTA protein
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has 691 aa and is a potent transcriptional factor consisting
of a DNA-binding domain at its N terminus, two putative
nuclear localization signals and a transactivation domain at
its C terminus. To date, a number of viral lytic genes,
including ORF50 itself, that can be regulated by RTA have
been identified (Bowser et al., 2006; Chang et al., 2002;
Chen et al., 2000; Deng et al., 2000, 2002; Duan et al.,
2001). RTA has been shown to transactivate its target
promoters either by binding directly to an RTA-responsive
element (RRE) or indirectly by interacting with cellular
proteins, such as KSHV RTA-binding protein (K-RBP)
(Wang et al., 2001b; Yang & Wood, 2007), CCAAT/
enhancer-binding protein-a (CEBP-a) (Wang et al., 2003a,
b), octamer-binding protein 1 (Oct-1) (Sakakibara et al.,
2001) and recombination signal-binding protein Jk (RBP-
Jk) (Liang & Ganem, 2004). RTA protein with its DNA-
binding domain recognizes RREs in target gene promoters,
and an AT-rich or A/T trinucleotide motif is considered to
be a feature of KSHV RREs that can be found in the ORF57
and K8 promoters (Liao et al., 2003; Lukac et al., 2001).
However, there is a lack of a consensus RRE sequence, as
substantial diversity can be observed in the RREs identified
in the promoters of various KSHV genes found to be
responsive to RTA. These include the PAN (polyadenylated
nuclear RNA) (Song et al., 2002), K12 (kaposin) (Chang
et al., 2002), K2 (viral interleukin-6) (Deng et al., 2002)
and K1 (Bowser et al., 2006) genes.
Epstein–Barr virus (EBV) Rta, a homologue of KSHV RTA,
also functions as an activator of viral lytic promoters. A
consensus EBV Rta-responsive element (EBV RRE),
GNCCN9GGNG, where N can be any nucleotide, has been
identified (Gruffat & Sergeant, 1994). Recently, the optimal
EBV RRE sequence, GTCC(C/A)(T/C)(C/G)N(A/G)NC(A/
G)(T/A)GGCG, was reported to be present in five EBV
lytic cycle promoters (Chen et al., 2005). Interestingly, a
CCN9GG-like sequence can also be found in the KSHV
ORF57 promoter (Fig. 1a). ORF57 is one of the KSHV lytic
genes and is highly responsive to RTA. It encodes a post-
transcriptional activator involved in mRNA export and
plays an important role in KSHV lytic replication.
Previously, we and others (Duan et al., 2001; Lukac et al.,
2001) have mapped a 40 bp segment of the ORF57
promoter encompassing nt 81904–81943 on the viral
genome as the target site for RTA binding and upregula-
tion of ORF57 transcription. Two RREs (ORF57-RRE1 and
ORF57-RRE2) were identified in this 40 bp segment (Fig.
1a). ORF57-RRE1 was found to share some homology with
the delayed early gene K8 promoter sequence (Lukac et al.,
2001; Wang et al., 2001a). ORF57-RRE2 was found to bind
not only RTA, but also interferon regulatory factor 7 (IRF-
7), and competition between RTA and IRF-7 affects
regulation of the ORF57 promoter by RTA (Wang et al.,
2005). Even though these two RREs are AT-rich, as
predicted for RREs, there is no similarity between them.
However, upon inspection of the ORF57 promoter, a
CCN9GG-like sequence distinct from ORF57-RRE1 and
-RRE2 was also found. We termed this CCN9GG-like motif
in the ORF57 promoter as ORF57-RRE3. In this study, we
characterized this third RRE in the ORF57 promoter and
found that it plays an important role in conferring
responsiveness of the promoter to KSHV RTA.
METHODS
Plasmids. An RTA expression plasmid (pCMVtagORF50) encoding
Flag-tagged full-length RTA has been described previously (Wang
et al., 2001a). The b-galactosidase expression plasmid pCMVb, which
was used for normalization of transfection efficiency, was purchased
from BD Clontech. All ORF57 reporter plasmids were cloned in the
pGL3-Basic vector (Promega), and p57p1, p57B1, p57B1M1 and
p57E have been described previously (Duan et al., 2001; Wang et al.,
Fig. 1. Sequence comparison of RREs. (a) The sequences of the three potential KSHV RREs (RRE1, RRE2 and RRE3) in the
ORF57 promoter are shown in bold italic and underlined. The RBP-Jk-binding site is indicated with double underlining. (b)
Alignment of potential KSHV RREs with homology to the EBV RRE CCN9GG sequence in the ORF57, K2, PAN, MIP and K12
promoters. Identical sequences are boxed. Numbers represent the nucleotide positions of the KSHV genome according to
GenBank accession no. U75698. The sequence of EBV RRE is in bold, where N can be any nucleotide.
RTA-responsive element in the KSHV lytic gene promoter
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2001a). Plasmids p57-3RRE, p57-3RRE1, p57B2 and p57-3RRE4
contained ORF57 upstream regions spanning nt 2184 to 220, 2163
to 220, 268 to 2184 and 2151 to 220, respectively (the putative
transcription start site at nt 82081 is designated +1). Plasmid
p57p1m2 contained the same ORF57 promoter region from 2525 to
273 as p57p1, but had mutations in ORF57-RRE2 (the T nucleotides
in positions 2141, 2143 and 2149 were replaced with C, and CTT at
nt 2145 to 2147 were replaced with AGC). Plasmids p57-3RRE3,
p57-3RRE2 and p57-3RRE03 contained the same ORF57 promoter
region as p57-3RRE, but p57-3RRE2 had a substitution in the RBP-
Jk-binding site (nt 2163 to 2151) with the PstI restriction enzyme
sequence, p57-3RRE3 had a deletion in ORF57-RRE2 (nt 2151 to
2138) and p57-3RRED3 had a deletion in ORF57-RRE3 (nt 2122 to
2137). Plasmid p57B2M contained the same ORF57 promoter region
as p57B2, but had mutations in ORF57-RRE1 as in the p57B1M1
construct.
Electrophoretic mobility shift assay (EMSA). Probes were
obtained by labelling double-stranded oligonucleotides (see Figs 2a
and 4a) with [a-32P]dATP (Amersham) using DNA polymerase I
Klenow fragment (New England BioLabs). Labelled probes were
incubated with purified His-tagged, full-length RTA protein, which
was expressed in Sf9 cells and purified using Ni-NTA (Promega), for
30 min in binding buffer [10 mM Tris/HCl (pH 7.5), 150 mM KCl,
5.7 mM MgCl2, 1 mM EDTA, 0.1 mg poly(dI/dC), 5 mg BSA,
0.38 mM dithiothreitol, 0.38 mM PMSF, 50 mM b-mercaptoethanol,
5% glycerol]. For competition assays, the purified Sf9/RTA protein
was incubated with non-radioactive competitor DNA for 30 min; the
labelled probe was then added and incubated for 30 min. The binding
mixtures were loaded onto a 4.5% polyacrylamide gel in 16 TGE
buffer [5 mM Tris base, 190 mM glycine, 1 mM EDTA (pH 8.3)].
After electrophoretic separation at 200 V, gels were transferred to
Whatman 3MM paper, dried and subjected to autoradiography with
Kodak X-ray film.
Transient chromatin immunoprecipitation (ChIP). ORF57
reporter plasmid and RTA expression plasmid were co-transfected
into 293T cells or TRExBJAB-RTA cells (provided by Dr Jae Jung,
University of Southern California, CA, USA) using Lipofectamine
2000 reagent (Invitrogen) or Nucleofector (Amaxa). Transfection
efficiency was approximately 90% for 293T cells and approximately
70% for TRExBJAB-RTA cells. At 24 h post-transfection, doxycy-
cline was added to the TRExBJAB-RTA cells to induce RTA
expression. At 40–48 h post-transfection, cells were fixed by the
addition of 37% formaldehyde to a final concentration of 1% for
10 min. The cross-linking reaction was stopped by adding glycine to
a final concentration of 0.125 M for 5 min. Cells were washed twice
with 16 ice-cold PBS and resuspended in cell lysis buffer [5 mM
PIPES (pH 8.0), 85 mM KCl, 0.5% NP-40, 1 mM PMSF, protease
inhibitor cocktail (Pierce)] for 10 min at 4 uC. After centrifugation,
the cell pellets were resuspended in nuclear lysis buffer [50 mM
Tris/HCl (pH 8.1), 10 mM EDTA, 1% SDS] and incubated for
10 min at 4 uC. The resulting solution was diluted 10-fold with
dilution buffer [16.7 mM Tris/HCl (pH 8.1), 167 mM NaCl,
1.2 mM EDTA, 0.01% SDS, 1.1% Triton X-100, 1 mM PMSF,
protease inhibitor cocktail] and sonicated. After centrifugation, the
supernatant was pre-cleared with mouse IgG (Santa Cruz) and
immobilized protein A (Pierce). Immunoprecipitation was per-
formed by incubation at 4 uC with anti-Flag M2 antibody
(Stratagene) or anti-His antibody (Clontech). Immune complexes
were collected by a further incubation with immobilized protein A
for 1–2 h at 4 uC. The beads were washed four times with IP buffer
[25 mM Tris/HCl (pH 7.2), 150 mM NaCl] and resuspended in
ImmunoPure IgG elution buffer (Pierce). After centrifugation, the
supernatant was neutralized with 1 M Tris/HCl (pH 7.2). RNase A
and NaCl were added, followed by incubation at 65 uC overnight to
reverse the cross-linked DNA–protein complex. Proteinase K
(Stratagene) was added, followed by incubation at 55 uC for 1–
2 h. DNA extraction was carried out using a miniprep kit (Qiagen)
and analysed by PCR using specific primers located in the reporter
vector. The DNA was quantified by TaqMan real-time PCR using
TaqMan PCR core reagents (Applied Biosystems). For calculation of
the relative DNA amount from quantitative real-time PCR, the Ct
(threshold cycle) value of antibody-precipitated sample was
normalized by the Ct value of the input, and the normalized Ct
value of p57-3RRED3 was compared with the normalized Ct value
of p57-3RRE. The mean±SD of the results for each promoter was
calculated from the results of two reactions obtained from three
different transfection experiments.
Cell culture, transfection and luciferase assay. BJAB cells (a
KSHV-negative cell line) were grown in RPMI 1640 (Gibco-BRL)
supplemented with 10% fetal bovine serum and 100 mg penicillin/
streptomycin (Mediatech) ml21 at 37 uC with 5% CO2. Transfection
of BJAB cells was carried out using Nucleofector (Amaxa) according
to the manufacturer’s recommendations. The transfection efficiency
was normalized using the b-galactosidase expression plasmid pCMVb
as an internal control. Luciferase activities were determined using a
Luciferase Assay System (Promega). Mean results were determined
from three independent experiments.
Fig. 2. Binding of RTA to the CCN9GG core sequence in vitro. (a)
Alignment of the ORF57-RRE3, K2-RRE and MIP-RRE
sequences. Identical nucleotides are indicated by vertical lines.
The synthetic oligonucleotide fragments of ORF57-RRE3, K2-
RRE and MIP-RRE used for EMSAs are capitalized and in bold.
(b–d) EMSA was carried out using full-length His-tagged RTA
expressed in Sf9 cells and 32P-labelled dsDNA probes. RTA was
shown to bind to ORF57-RRE3 and also to K2-RRE and MIP-
RRE. Lanes 1, 8 and 15, 32P-labelled probe alone (control); lanes
2–4, 9, 10, 16, 17, increasing amounts of RTA incubated with
probe; lanes 5–7, 11–14 and 18–21, 50- and 100-fold excess
unlabelled specific or non-specific (AP1) competitor incubated in
the presence of purified RTA. Arrows indicate the RTA–DNA
complex.
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RESULTS
A CCN9GG-like consensus sequence can be
identified in a number of KSHV promoters
To examine whether KSHV RTA binds directly to the RRE3
sequence of the ORF57 promoter, we performed an EMSA
using purified, His-tagged, full-length RTA protein
expressed in recombinant baculovirus-infected Sf9 cells.
Double-stranded ORF57-RRE3 oligonucleotides (18 bp;
Fig. 2a) were labelled and incubated with binding buffer
either alone or with increasing amounts of RTA. The
ORF57-RRE3 oligonucleotide demonstrated dose-depend-
ent binding to RTA (Fig. 2b, lanes 1–4). To demonstrate the
specificity of RTA binding to ORF57-RRE3, excess amounts
of unlabelled ORF57-RRE3 and AP1-binding sequence were
used as specific and non-specific competitors, respectively,
in competition experiments. The interaction of RTA and
ORF57-RRE3 was shown to be specific as it could be
competed out by homologous unlabelled oligonucleotide,
but not by AP1-specific oligonucleotide (Fig. 2b, lanes 5–7).
To confirm further that RTA binds to a CCN9GG-like
motif, 18 bp oligonucleotide fragments of K2-RRE and
MIP (macrophage inflammatory protein)-RRE (Fig. 2a)
were used for an EMSA. Similar to ORF57-RRE3, strong
binding to RTA was observed, demonstrating that K2-RRE
and MIP-RRE containing a CCN9GG-like sequence are also
RTA targets, and this specificity was confirmed by EMSA
using competitors (Fig. 2c, d). Our results indicated that
CCN9GG is a potentially conserved motif of KSHV RRE in
addition to AT-rich sequences identified previously, and
that the CCN9GG-like motif could be a third RRE located
in the ORF57 promoter.
ORF57-RRE3 is required for RTA binding to the
ORF57 promoter
To confirm further that ORF57-RRE3 mediates RTA
binding to the ORF57 promoter in vivo, transient ChIP
was carried out in 293T and TRExBJAB-RTA cells. The
reporter construct containing the ORF57 promoter, shown
in Fig. 3(a), and the Flag-tagged, full-length RTA expression
plasmid were co-transfected into 293T cells. The presence of
ORF57 promoter DNA fragments within the immunopre-
cipitated complex was confirmed by PCR amplification. As
shown in Fig. 3(a, upper panel, lane 1), a strong band was
detected in the presence of RTA and the p57-3RRE plasmid
containing all three RREs in the ORF57 promoter. The
negative control with transfection in the absence of antibody
failed to recover any PCR product (Fig. 3a, lane 2). In
contrast to p57-3RRE, transfection of p57-3RRED3, which
lacked RRE3 in the ORF57 promoter element, appeared to
be less efficient in binding to RTA and resulted in a weaker
amplified band (Fig. 3a, lower panel, lane 1). This was also
confirmed by real-time PCR to quantify the amount of
precipitated DNA from 293T and TRExBJAB-RTA cells,
whereby the RRE3-lacking DNA fragment resulted in
approximately 65% reduction in binding to RTA in 293T
cells and 85% reduction in TRExBJAB-RTA cells (Fig. 3b).
These results suggested that ORF57-RRE3 is required for
efficient binding of RTA to the ORF57 promoter.
RTA can bind to each of the three ORF57 RREs
independently
In an earlier study, we demonstrated that RTA protein
expressed in Escherichia coli can bind to the ORF57
promoter fragment 57R consisting of ORF57-RRE1 and the
RBP-Jk-binding site (Fig. 4a) (Wang et al., 2005). The
results in Fig. 2 demonstrated that the RTA protein
expressed in baculovirus-infected Sf9 cells could bind to
RRE3 in vitro. To characterize further the binding of RTA
to each of the three RRE elements, an EMSA was carried
out with DNA fragments containing each of these elements
(Fig. 4a). Multiple high-molecular-mass shifted bands were
observed with the 57R labelled probe (Fig. 4b).
Interestingly, we also observed interaction of RTA and
RRE1, which lacked the RBP-Jk consensus sequence, but
only a single complex was detected (Fig. 4c). Similarly, only
one band was detected with the ORF57-RRE2 probe
(Fig. 4d). Figs 2 and 4 suggest that Sf9/RTA can bind
directly to each of the three ORF57 RREs. This binding did
Fig. 3. Binding of RTA to the ORF57 promoter RREs in vivo. (a) A
transient ChIP assay was carried out in 293T cells transfected with
the reporter plasmids p57-3RRE and p57-3RRED3 as indicated,
together with Flag-tagged full-length RTA expression plasmid.
RTA–DNA complexes were specifically precipitated with or
without anti-Flag antibody. The precipitated DNA was recovered
by PCR with specific primers located in the backbone of the
reporter vector. (b) Taqman real-time PCR was performed to
quantify the immunoprecipitated promoter DNA from transfected
293T and TRExBJAB-RTA cells.
RTA-responsive element in the KSHV lytic gene promoter
http://vir.sgmjournals.org 947
not require the RBP-Jk consensus sequence, but the
presence of the RBP-Jk-binding site may contribute to
the formation of multiple complexes.
Binding of RTA to ORF57-RRE3 is weaker than to
ORF57-RRE1 and -RRE2
To investigate further the differential ability of each ORF57
RRE to bind RTA, cross-competition assays were carried
out. As expected, the binding of RTA to each ORF57 RRE
probe was competed out efficiently by its homologous
unlabelled oligonucleotide (Fig. 5, lanes 2–5, 17–20 and 32–
35). ORF57-RRE1 binding to RTA was reduced by
approximately 50% with an excess of ORF57-RRE2
competitor (Fig. 5, lanes 6–9), and ORF57-RRE2 binding
was reduced by approximately 80% with an excess of
ORF57-RRE1 competitor (Fig. 5, lanes 21–24) based on
quantification of the bands. The binding of RTA to ORF57-
RRE3 was efficiently competed out by unlabelled ORF57-
RRE1 or ORF57-RRE2 (Fig. 5, lanes 36–43). However,
ORF57-RRE3 was unable to compete for binding to RTA
with either ORF57-RRE1 or ORF57-RRE2 (Fig. 5, lanes 10–
13 and 25–28, respectively). Taken together, these results
showed that the RTA-binding affinity of ORF57-RRE1 was
comparable to that of ORF57-RRE2, but the RTA-binding
affinity of ORF57-RRE1 and ORF57-RRE2 appeared to be
much stronger compared with that of ORF57-RRE3.
Two RREs are required for RTA-mediated
transactivation of the ORF57 promoter
To verify that the binding of RTA to ORF57-RRE3 plays a role
in transactivation of the ORF57 promoter, transient transfec-
tion experiments were carried out by co-transfection of the
RTA expression plasmid with various reporter constructs of
the ORF57 promoter as shown in Fig. 6(a). The p57-3RRE
reporter, which contains the 40 bp segment, was induced
effectively by RTA in BJAB cells (56-fold; Fig. 6b).
Surprisingly, the p57-3RRE1 reporter, lacking ORF57-RRE1,
was still transactivated effectively by RTA (63-fold), even
though the AT-rich palindrome of ORF57-RRE1 has been
considered a critical region for binding and transactivation by
RTA (Lukac et al., 2001). Induction of the p57B2 reporter,
with deletion of a 48 bp segment in the C-terminal ORF57
promoter, remained high (60-fold). The reporter p57B2M
with mutations in ORF57-RRE1, and p57B1 reporter with a
deleted ORF57-RRE3, remained highly responsive to RTA,
comparable to the levels for p57B2. However, removal of
ORF57-RRE3 and mutation of ORF57-RRE1 (p57B1M1)
significantly reduced the promoter’s responsiveness to RTA.
Fig. 4. Binding of RTA to ORF57-RRE1 and -RRE2 is independent of the RBP-Jk-binding site in vitro. (a) Solid lines show the
four DNA fragments (57R, RRE1, RRE2 and RRE3) that were labelled with 32P and used as probes for EMSAs. (b–d) EMSA
was performed with RTA and the three DNA fragments, p57R (b), RRE1 (c) and RRE2 (d). The conditions used for EMSA were
as described in Fig. 2. Unlabelled probes were used as specific competitors and AP1 DNA was used as a negative control.
Arrows indicate the RTA–DNA complex.
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These results suggest that ORF57-RRE1 or ORF57-RRE3
alone is not sufficient for efficient RTA transactivation, but
that at least one of these two elements in combination with
ORF57-RRE2 is required. This was confirmed by the p57E
reporter containing ORF57-RRE3 alone, which showed a
dramatic reduction in transactivation.
To confirm the role of ORF57-RRE2 in RTA-mediated
transactivation, the ORF57-RRE2-deleted reporter p57-
3RRE3 was used. Transactivation of p57-3RRE3 reporter
by RTA was almost abolished (Fig. 6b). To confirm that the
loss of transactivation response was not a result of the
deletion, which shortened the length of the ORF57
Fig. 5. Comparison of the binding affinity of RTA to ORF57-
RRE1, -RRE2 and -RRE3. A cross-competition EMSA was used
to determine the differential binding ability of RTA to the three
RREs. Purified RTA protein (500 ng) was incubated with 40 fmol
labelled probe in the absence or presence of homologous or non-
homologous cold competitors. Increasing amounts (5, 25, 50
and 100) of various non-homologous cold competitors were
added. Non-specific competitor AP1 DNA was used a negative
control and the fold excess relative to the labelled probes is
indicated. Lanes 1, 16 and 31 represent probe alone (controls).
RTA-responsive element in the KSHV lytic gene promoter
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promoter between ORF57-RRE1 and -RRE3, we tested the
p57p1m2 reporter, which contained six nucleotide sub-
stitutions in ORF57-RRE2 but had overall promoter length
that remained the same. As expected, the RTA responsive-
ness of p57p1m2 was still significantly reduced compared
with p57p1, which acted as a positive control (Fig. 6c).
These results suggested that ORF57-RRE2 is essential for
RTA-mediated transactivation.
RTA-mediated transactivation of the ORF57
promoter requires the RBP-Jk-binding site and
two RREs
RBP-Jk has been demonstrated to be a critical cellular
factor for RTA-mediated transactivation of the ORF57
promoter by binding to the RBP-Jk-binding site. The two
promoter reporter constructs p57-3RRE1 and p57B1, both
containing the RBP-Jk-binding site, were strongly activated
by RTA (Fig. 6b), suggesting that the RBP-Jk-binding site
is important in addition to the RREs. To define further the
role of the RBP-Jk-binding site and the two RREs in
mediating RTA transactivation, the reporter p57-3RRE4,
with a deletion of the upstream region of ORF57-RRE2
including the RBP-Jk-binding site and ORF57-RRE1, was
tested. As expected, this reporter lost its responsiveness to
RTA, even though both ORF57-RRE2 and ORF57-RRE3
were intact. In addition, RTA inducibility was low with the
p57-3RRE2 reporter, which has a deletion in the RBP-Jk-
binding site but an intact ORF57-RRE1, -RRE2 and -RRE3
(Fig. 6b). This was expected, as RBP-Jk is well established
Fig. 6. Two RTA-responsive elements and the
RBP-Jk-binding site are required for RTA-
mediated transactivation. (a) Schematic rep-
resentation of the ORF57 promoter reporter
constructs and various deletion and site-
directed mutagenesis clones used in the
transient transfection analysis. Solid lines
indicate different regions of the ORF57
promoter segment with various deletions (thin
lines) or mutated regions (hatched boxes). The
responsiveness of each reporter to RTA
transactivation is indicated. (b, c) BJAB cells
were used to analyse the promoter activity of
different ORF57 reporter constructs. The total
DNA amount used in each transfection was
normalized by adding pCMVTag2A vector.
Transfection of BJAB cells was carried out
with 0.8 mg promoter reporter and 1 mg RTA
expression plasmid. Luciferase activity was
measured at 48 h post-transfection.
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as a co-activator of RTA that recognizes the consensus
sequence located between ORF57-RRE1 and ORF57-RRE2
that regulates ORF57 transcription (Carroll et al., 2006;
Liang et al., 2002). Interestingly, mutations in RRE2
(p57p1m2) and mutation/deletion in RRE1 and RRE3
(p57B1M1) affected the transcriptional induction of the
ORF57 promoter by RTA (Fig. 6b, c). The responsiveness
of these two promoter constructs to RTA was reduced
substantially. Taken together, our results showed that RBP-
Jk plays an essential role in RTA-mediated ORF57
transactivation, but that the presence of two RREs
(RRE1/RRE2 or RRE2/RRE3) is also necessary.
DISCUSSION
Role of ORF57 RREs in RTA-mediated
transactivation of the ORF57 promoter
In this study, we identified a third RRE, ORF57-RRE3, in the
ORF57 promoter. It has a high G+C content, which
distinguishes it from the other two previously characterized
RREs in the ORF57 promoter. Similar RREs with high G+C
content have been found in the promoter elements of several
other KSHV genes that are responsive to KSHV RTA.
The three ORF57 RREs are located in close proximity to
each other in the ORF57 promoter and each has a unique
sequence. Among the three RREs analysed, RRE2 seems to
be essential for RTA-mediated transactivation. However,
the presence of RRE2 alone was insufficient for transacti-
vation, and the presence of either RRE1 or RRE3 was also
required for RRE2 to be fully responsive to RTA. It is
possible that, for the ORF57 promoter, the RTA protein
may require more than one RRE for it to regulate its
expression; whether this is required for other RTA-
responsive promoters needs to be determined. Our results
also suggested that RRE1 and RRE3 may play similar roles,
as each could be replaced by the other in combination with
RRE2 to mediate RTA transactivation; the presence of at
least two RREs was required for transactivation. We found
that deletion of ORF57-RRE1 alone did not affect ORF57
transactivation mediated by RTA (Fig. 6a), which is in
contrast to an earlier report, demonstrating that ORF57-
RRE1 was critical for RTA binding and transactivation
(Lukac et al., 2001). However, these authors tested an
isolated RRE1/RBP-Jk element, thus making any direct
comparison with our ORF57 reporter studies difficult.
We also observed that the amount of RTA bound to the
promoter element containing RRE1 and RRE2 alone was
less than with the intact promoter containing all three
RREs (Fig. 3), although their levels of transactivation by
RTA were similar. It is possible that the amount of RTA
bound to RRE1 and RRE2 without RRE3 is adequate to
reach the threshold level of RTA needed to be recruited to
the promoter element for it to mediate full transactivation.
Alternatively, it is possible that two adjacent RREs are
needed for the RTA complex to bind optimally, as RTA has
recently been reported to multimerize in vitro (Bu et al.,
2007; Liao et al., 2003). In fact, we observed RTA
multimerization in EMSAs (Fig. 4b) with multiple high-
molecular-mass shifted bands using a DNA probe contain-
ing ORF57-RRE1 and the RBP-Jk-binding sites. These
complexes could be due to spontaneous multimerization of
RTA as described previously (Bu et al., 2007; Liao et al.,
2003), but whether such complexes exist in vivo and
participate in binding to the two RREs and in transactiva-
tion of the ORF57 promoter needs to be investigated
further.
In spite of the similar roles played by ORF57-RRE1 and
-RRE3 in mediating transactivation, the binding affinities
of RTA to ORF57-RRE1 and -RRE3 were distinct, raising
the possibility that the binding affinity of RTA to different
RREs may not be directly proportional to the level of RTA-
mediated transactivation. Transactivation function may
require the presence of additional factors other than RTA;
these may include both viral and cellular factors. One such
factor is RBP-Jk, which was shown to be a critical
transcriptional factor interacting with RTA to bind to the
RBP-Jk-binding site between ORF57-RRE1 and -RRE2 to
activate ORF57 transcription (Carroll et al., 2006; Liang
et al., 2002). Indeed, our data revealed that RTA-mediated
transcription of the ORF57 promoter could proceed only
in the presence of all three elements – the RBP-Jk-binding
site, ORF57-RRE2 and either ORF57-RRE1 or -RRE3.
Taken together, ORF57-RRE1 and -RRE3 may play a
secondary but necessary role to enable the RTA–RBP-Jk
complex to bind to ORF57-RRE2 and the RBP-Jk-binding
site in the ORF57 promoter to mediate transactivation. We
are investigating further the exact roles of ORF57-RRE1
and -RRE3 in RTA-mediated transactivation.
Conserved KSHV RTA-binding sequence
KSHV RREs have been studied extensively in recent years
(Chang et al., 2005; Liao et al., 2003; Ziegelbauer et al.,
2006). They have been found to be diverse and to lack a
consensus sequence, but the exact motif mediating RTA
binding and transactivation is still ambiguous. In contrast,
the EBV Rta RRE sequence, GNCCN9GGNG, has been
identified as being responsive to EBV Rta in several EBV
lytic cycle promoters. Our finding that a CCN9GG-like
sequence can also be used by KSHV RTA to mediate
transactivation of the ORF57 promoter suggests that EBV
and KSHV RREs may share sequence homology, and it is
possible that the CCN9GG-like motif may also be found in
other RTA-responsive promoters. Indeed, in the KSHV
PAN promoter, the major sequence in the PAN RRE
identified previously for RTA recognition and transactiva-
tion contains the ACCN9GG consensus sequence (Fig. 1b)
(Song et al., 2002). In addition, it has been reported that
another RTA-responsive promoter, MIP, lost its respon-
siveness following a deletion in the region encompassing nt
27 855–27 876 of the viral genome (Chang et al., 2005). We
found that this region contains not only the RBP-Jk-
RTA-responsive element in the KSHV lytic gene promoter
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binding site, but also the ACCN9GG sequence, and have
confirmed that RTA can bind to the MIP ACCN9GG motif
alone using an EMSA. In contrast, Chang et al. (2005)
failed to observe an interaction between the RTA protein
and a DNA probe from the MIP promoter; this is not
unexpected because of the absence of the ACCN9GG motif
in the DNA probe that was used in the EMSA.
Interestingly, the ACCN9GG motif can also be found in
the K2-RRE previously identified by Deng et al. (2002), and
we have now shown that RTA binds to the K2 DNA
containing the ACCN9GG sequence (Fig. 2). Taken
together, these results suggest that the KSHV ACCN9GG
motif is an important RTA target.
Studies of the EBV Rta-responsive promoters that contain
the recognition sequence GNCCN9GGNG have shown that
the differences in their binding affinities and responsive-
ness to Rta transcription activation could be attributed to
variation in the N9 sequence within each promoter element
(Chen et al., 2005). Similarly, for KSHV, the five promoters
containing the consensus sequence CACC(A/
G)NTNGGN(C/G)NGG(T/C) that we identified here
displayed variations in their N9 sequences (Fig. 1b), and
this variation may play a role in their differential
responsiveness to RTA transactivation. Indeed, it was
found that the PAN-RRE had a stronger binding affinity
and transactivation by RTA compared with the K12- and
K2-RREs, although all of these RREs contained the
CACC(A/G)NTNGGN(C/G)NGG(T/C) motif (Song et al.,
2003). It is possible that the PAN N9 sequence is optimal
for RTA binding; it is also possible that cellular factors may
play a role in the differential binding and responsiveness of
these promoters to RTA. A number of cellular proteins,
such as K-RBP, RBP-Jk, Oct-1, AP1, SP1 and CEBP-a, are
known to regulate RTA-mediated transactivation (Chen et
al., 2000; Liang & Ganem, 2004; Sakakibara et al., 2001;
Wang et al., 2003a, b; Yang & Wood, 2007), and some of
their binding motifs are found to be present in the vicinity
of the CACC(A/G)NTNGGN(C/G)NGG(T/C) motif.
Thus, the combination of RTA binding to these motifs
with the presence of cellular factors may confer optimal
activation of the promoter. Taken together, it is likely that
the ability of RTA to mediate transactivation is distinct
from its ability to bind to RREs and its binding affinity to
these elements. Its ability to uncouple these two functions
may play a role in its ability to regulate lytic gene
expression at different stages of the KSHV life cycle.
In summary, we have identified a new RRE sequence
containing a GC-rich sequence in five KSHV lytic gene
promoters based on sequence homology to the consensus
EBV RRE. Whether this consensus RRE sequence,
CACC(A/G)NTNGGN(C/G)NGG(T/C), is present in other
RTA target genes and whether there are optimal N
sequences required remain to be determined. This is also
the first report to demonstrate that KSHV RTA-mediated
transcription requires two RREs in close proximity to each
other. A better understanding of the role played by RTA
and the various RREs will be needed to elucidate the
mechanism of RTA-mediated transactivation and induc-
tion of KSHV lytic replication.
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